Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer

Phase 2 Unknown 20 enrolled Zhongda Hospital

NaSingle-groupOpen-labelTreatment

Summary

This study is a single-arm, open-label, exploratory clinical study, the main purpose is to evaluate the combination of envafolimab, lenvatinib VP-16 in the treatment of platinum-resistant recurrent epithelial ovarian cancer，primary fallopian tube cancer and primary peritoneal carcinoma.

Timeline

Start: 2022-06-30
Primary completion: 2022-12-30
Completion: 2023-12-30

Publications

Ding B, Yu T, Zheng S, Xu J, Ji F, Lin H, Zhao X, Qiu S, Shen Y. Combination therapy for platinum-resistant ovarian cancer: a novel at-home regimen with envafolimab, lenvatinib, and etoposide. Oncologist. 2025 Sep 1;30(9):oyaf210. doi: 10.1093/oncolo/oyaf210.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Envafolimab	Monoclonal antibody	400 mg	Subcutaneous
Subject	Etoposide	Small molecule	50 mg	Oral
Subject	Lenvatinib	Small molecule	8 mg	Oral
Subject	Lenvatinib	Small molecule	12 mg	Oral

Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer

Summary

Timeline

Publications

Drugs

Indications